<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5064287a-af00-4516-a8a3-f430f176e06e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use EMERPHED and EMERPHED-PFS safely and effectively. See full prescribing information for EMERPHED and EMERPHED-PFS.<br/>EMERPHED<sup>®</sup> (ephedrine sulfate) injection, for intravenous use.<br/>EMERPHED®-PFS (ephedrine sulfate injection), for intravenous use.<br/>Initial U.S. Approval: 2016</title>
   <effectiveTime value="20240916"/>
   <setId root="14601778-93ac-43ec-b66b-5a942317133f"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="620714787" root="1.3.6.1.4.1.519.1"/>
            <name>Nexus Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="620714787" root="1.3.6.1.4.1.519.1"/>
                        <name>Nexus Pharmaceuticals, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="14789-252" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="14789-251" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="e75f135e-5f1b-43c5-a31a-2e477bcdb00a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240918"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="14789-252" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Emerphed<suffix>-PFS</suffix>
                        </name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ephedrine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U6X61U5ZEG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ephedrine Sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GN83C131XS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="14789-252-09" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="14789-252-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230301"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213407" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="14789-251" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Emerphed<suffix>-PFS</suffix>
                        </name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ephedrine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U6X61U5ZEG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ephedrine Sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GN83C131XS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="14789-251-09" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="14789-251-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230301"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213407" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="a74f9dd0-4548-4c61-8c9e-ae01b0d650bb"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1. INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>EMERPHED and EMERPHED-PFS is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>EMERPHED and EMERPHED-PFS is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. (<linkHtml href="#s1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="ac1e58f9-6724-456c-b708-93453de282b4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2. DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20240918"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>This is a premixed formulation. Do not dilute prior to use.</item>
                           <item>Discard any unused portion of EMERPHED or EMERPHED-PFS.</item>
                           <item>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</item>
                           <item>EMERPHED and EMERPHED-PFS is a clear, colorless solution. Do not use if the solution is not clear or if particulate matter is present.</item>
                           <item>The single-dose prefilled syringe is intended for use in one patient during one surgical procedure.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="58669e97-7803-407b-9423-7398cb05f6cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosage and Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>This is a premixed formulation. Do not dilute prior to use.</item>
                           <item>Discard any unused portion of EMERPHED.</item>
                           <item>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</item>
                           <item>The single-dose prefilled syringe is intended for use in one patient during one surgical procedure.</item>
                        </list>
                        <paragraph>EMERPHED is a clear, colorless solution. Do not use if the solution is not clear or if particulate matter is present.</paragraph>
                     </text>
                     <effectiveTime value="20240918"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="cbe2e725-40e2-4221-8fdb-de334626c6d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosing for the Treatment of Clinically Important Hypotension in the Setting of Anesthesia
</title>
                     <text>
                        <paragraph>The recommended dosages for the treatment of clinically important hypotension in the setting of anesthesia is an initial dose of 5 mg to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adjust dosage according to the blood pressure goal (i.e., titrate to effect).</item>
                        </list>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="9a7f7104-67c7-47dc-a250-8668eddd480a"/>
                     <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
                     <title>2.3 Instructions for Use of Prefilled Syringe
</title>
                     <text>
                        <paragraph>The proper method of administration of EMERPHED-PFS injection is described in the following instructions.</paragraph>
                        <paragraph>For each single-dose prefilled syringe:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Remove syringe from tray and check that it is not damaged or leaking.</item>
                           <item>Inspect drug product in glass syringe for any visible particulate matter or discoloration prior to use. Discard if particulate matter or discoloration is present.</item>
                           <item>Do not remove the tamper evident seal. Push plunger rod slightly in to break the stopper loose while tip cap is still on.</item>
                           <item>Hold the syringe upright on the syringe barrel (C). With the other hand, take hold of the cap (A) and twist off cap counterclockwise from syringe tip (see Figure 1).<renderMultiMedia referencedObject="L3ba4dbe2-d3f5-402f-9033-7ce9a4e569b7"/>
                           </item>
                           <item>Once cap (A) is off, DO NOT TOUCH THE STERILE SYRINGE TIP (Luer-Lok) (B) (see Figure 2).<renderMultiMedia referencedObject="Ld429d0b3-581a-43a7-8c5d-ef27f38f5ffc"/>
                           </item>
                           <item>Discard the tip cap.</item>
                           <item>Expel air bubble.</item>
                           <item>Adjust dose into sterile material (if applicable).</item>
                           <item>Connect the syringe to an appropriate intravenous connection.<list listType="unordered" styleCode="Square">
                                 <item>Before injection, ensure that the syringe is securely attached to the needle or needleless luer access device (NLAD).</item>
                              </list>
                           </item>
                           <item>Depress plunger rod to deliver medication. Ensure that pressure is maintained on the plunger rod during the entire administration.</item>
                           <item>Remove syringe from NLAD (if applicable) and discard into appropriate receptacle.<list listType="unordered" styleCode="Square">
                                 <item>To prevent needle stick injuries, do not recap needle when needle is connected to syringe.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="underline">NOTE</content>: All steps must be done sequentially</paragraph>
                              <list listType="unordered" styleCode="Square">
                                 <item>Do not re-sterilize syringe</item>
                                 <item>Do not use this product on a sterile field</item>
                                 <item>Do not introduce any other fluid into the syringe at any time</item>
                                 <item>This product is for single dose only</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20240918"/>
                     <component>
                        <observationMedia ID="L3ba4dbe2-d3f5-402f-9033-7ce9a4e569b7">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Ld429d0b3-581a-43a7-8c5d-ef27f38f5ffc">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="f1698f25-608c-4587-82d1-8b584bbeafd9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3. DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>EMERPHED (ephedrine sulfate injection) is a clear, colorless solution available as:</paragraph>
                  <list listType="unordered">
                     <item>A single-dose vial that contains 50 mg/10 mL (5 mg/mL) ephedrine sulfate, equivalent to 38 mg/10 mL (3.8 mg/mL) ephedrine base.</item>
                  </list>
                  <paragraph>EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless solution available as:</paragraph>
                  <list listType="unordered">
                     <item>A single-dose 5 mL prefilled syringe that contains 25 mg/5 mL (5 mg/mL) ephedrine sulfate, equivalent to 19 mg/5 mL (3.8 mg/mL) ephedrine base.</item>
                     <item>A single-dose pre-filled syringe that contains 50 mg/10 mL (5 mg/mL) ephedrine sulfate, equivalent to 38 mg/10 mL (3.8 mg/mL) ephedrine base.</item>
                  </list>
               </text>
               <effectiveTime value="20240917"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 50 mg/10 mL ephedrine sulfate, equivalent to 38 mg/10 mL ephedrine base in a single-dose vial (5 mg/ mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base); a 25 mg/5 mL (5 mg/mL) ephedrine sulfate in a 5 mL single-dose prefilled syringe; and a 50 mg/10 mL (5 mg/mL) ephedrine sulfate in a 10 mL single-dose prefilled syringe. (<linkHtml href="#s6">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="c352aed0-cf25-4f5c-addf-541df2d4dace"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4. CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>None
</paragraph>
               </text>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#s7">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="18339513-2890-402f-9d76-7a80c33d3ae8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5. WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pressor Effects with Concomitant Use with Oxytocic Drugs:</content> Pressor effect of sympathomimetic pressor amines is potentiated (<linkHtml href="#s9">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Tachyphylaxis and Tolerance:</content> Repeated administration of EMERPHED and EMERPHED-PFS may cause tachyphylaxis (<linkHtml href="#s10">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s9">
                     <id root="badcc707-3d6d-4fed-b1af-0ab0a9768fd5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Pressor Effect with Concomitant Oxytocic Drugs
</title>
                     <text>
                        <paragraph>Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [<content styleCode="italics">see Drug Interactions (<linkHtml href="#s13">7</linkHtml>)</content>]. Some of these patients experienced a stroke. Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and an oxytocic.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="245fe65f-e85b-4048-b3d2-7f37c4871807"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Tolerance and Tachyphylaxis
</title>
                     <text>
                        <paragraph>Data indicate that repeated administration of ephedrine can result in tachyphylaxis. Be aware of this possibility when treating anesthesia-induced hypotension with EMERPHED and EMERPHED-PFS and be prepared with an alternative pressor to mitigate unacceptable responsiveness.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="6bc2742e-8619-477d-9a23-171aea52482d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk of Hypertension When Used Prophylactically
</title>
                     <text>
                        <paragraph>When used to prevent hypotension, ephedrine has been associated with an increased incidence of hypertension compared with when ephedrine is used to treat hypotension.
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="41eaca02-0036-4712-a544-a09d6985f89e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6. ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal disorders:</content> Nausea, vomiting
</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac disorders:</content> Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability 
</paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous system disorders:</content> Dizziness
</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric disorders:</content> Restlessness
</paragraph>
               </text>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions during treatment : nausea, vomiting, and tachycardia. (<linkHtml href="#s12">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="Bold Italics">www.fda.gov/medwatch</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="c20e1224-9f39-4afb-a1d2-e89d87f25dfc"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7. DRUG INTERACTIONS
</title>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col width="26.400%" align="left"/>
                        <col width="73.600%" align="left"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center" valign="top">
                              <content styleCode="bold">Interactions that Augment the Pressor Effect</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Oxytocin and oxytocic drugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine). Some of these patients experienced a stroke.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and an oxytocic.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Clonidine, propofol, monoamine oxidase inhibitors (MAOIs ), atropine</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">These drugs augment the pressor effect of ephedrine.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and any of these drugs.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="center" valign="top">
                              <content styleCode="bold">Drugs that Antagonize the Pressor Effect</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">These drugs antagonize the pressor effect of ephedrine.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and any of these drugs.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="center" valign="top">
                              <content styleCode="bold">Other Drug Interactions</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Guanethidine</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">EMERPHED and EMERPHED-PFS may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Rocuronium</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">EMERPHED and EMERPHED-PFS may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Be aware of this potential interaction. No treatment or other interventions are needed.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Epidural anesthesia</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">EMERPHED and EMERPHED-PFS may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Monitor and treat the patient according to clinical practice.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Theophylline</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Concomitant use of EMERPHED and EMERPHED-PFS may increase the frequency of nausea, nervousness, and insomnia.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                              <content styleCode="bold">Cardiac glycosides</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Clinical Impact:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Giving EMERPHED and EMERPHED-PFS with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">
                              <content styleCode="italics">     Intervention:</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">Carefully monitor patients on cardiac glycosides who are also administered ephedrine.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20240916"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Interactions that Augment Pressor Effect:</content> clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure. (<linkHtml href="#s13">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Interactions that Antagonize the Pressor Effect:</content> Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure. (<linkHtml href="#s13">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Guanethidine:</content> EMERPHED and EMERPHED-PFS may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly.</item>
                           <item>
                              <content styleCode="underline">Rocuronium:</content> EMERPHED and EMERPHED-PFS may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed.</item>
                           <item>
                              <content styleCode="underline">Epidural anesthesia:</content> EMERPHED and EMERPHED-PFS may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice.</item>
                           <item>
                              <content styleCode="underline">Theophylline:</content> Concomitant use of EMERPHED and EMERPHED-PFS may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</item>
                           <item>
                              <content styleCode="underline">Cardiac glycosides:</content> Giving EMERPHED and EMERPHED-PFS with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered EMERPHED and EMERPHED-PFS.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="6f0cb40d-b194-4bb1-9565-4f7598f80713"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8. USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20240916"/>
               <component>
                  <section ID="s15">
                     <id root="12f9a701-0d9c-4175-9830-47cc86aa17f9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20240916"/>
                     <component>
                        <section ID="s16">
                           <id root="1986dc69-f897-40c8-92d3-f9c240358c45"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, there are clinical considerations due to underlying conditions [<content styleCode="italics">see <linkHtml href="#s17">Clinical Considerations</linkHtml>
                                 </content>]. In animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (MRHD) of 50 mg/day). No malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the MRHD, respectively [<content styleCode="italics">See <linkHtml href="#s19">data</linkHtml>
                                 </content>].</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s17">
                           <id root="9131fc15-2228-44ee-8a56-f65569e38ea8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                           <component>
                              <section ID="e18">
                                 <id root="c4dd96f7-7eda-49fe-8c5e-4c0afc260e58"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated maternal and/or embryofetal risk</content>
                                    </paragraph>
                                    <paragraph>Untreated hypotension associated with spinal anesthesia for cesarean section is associated with an increase in maternal nausea and vomiting. A decrease in uterine blood flow due to maternal hypotension may result in fetal bradycardia and acidosis.</paragraph>
                                 </text>
                                 <effectiveTime value="20240916"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s18">
                                 <id root="bf661a0e-d3a1-4d7a-93a8-f623346bd734"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. These reports describe umbilical artery pH of ≤7.2 at the time of delivery <content styleCode="italics">[see Clinical Pharmacology <linkHtml href="#s32">12.3</linkHtml>]</content>. Monitoring of the newborn for signs and symptoms of metabolic acidosis may be required. Monitoring of infant's acid-base status is warranted to ensure that an episode of acidosis is acute and reversible.</paragraph>
                                 </text>
                                 <effectiveTime value="20240916"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s19">
                           <id root="24ba9b08-89cd-4892-b4a4-aa4ec40410d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                           <component>
                              <section ID="s20">
                                 <id root="f0454b23-a2c1-46f8-8f5a-6197436e4731"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Decreased fetal body weights were observed when pregnant rats were administered intravenous bolus doses of 60 mg/kg ephedrine sulfate (12 times the maximum recommended human dose (MRHD) of 50 mg based on body surface area) from Gestation Day 6-17. This dose was associated with evidence of maternal toxicity (decreased body weight of dams and abnormal head movements). No malformations or fetal deaths were noted at this dose. No effects on fetal body weight were noted at 10 mg/kg (1.9 times the MRHD of 50 mg).</paragraph>
                                    <paragraph>No evidence of malformations or embryo-fetal toxicity were noted in pregnant rabbits administered intravenous bolus doses up to 20 mg/kg ephedrine sulfate (7.7 times the maximum recommended human dose (MRHD) of 50 mg based on body surface area) from Gestation Day 6-20. This dose was associated with expected pharmacological maternal effects (increased respiration rate, dilated pupils, piloerection).</paragraph>
                                    <paragraph>Decreased fetal survival and body weights in the presence of maternal toxicity (increased mortality) were noted when pregnant dams were administered intravenous bolus doses of 60 mg/kg epinephrine sulfate (approximately 12 times the MRHD based on body surface area) from GD 6 through Lactation Day 20. No adverse effects were noted at 10 mg/kg (1.9 times the MRHD).</paragraph>
                                 </text>
                                 <effectiveTime value="20240916"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="f99910e3-04a4-4ce0-9bd9-707730ea8805"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20240916"/>
                     <component>
                        <section ID="s22">
                           <id root="cdf2e6e9-7a55-4b65-a2dc-a89aaf890123"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>A single published case report indicates that ephedrine is present in human milk. However, no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMERPHED or EMERPHED-PFS and any potential adverse effects on the breastfed child from EMERPHED and EMERPHED-PFS or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="b41bdaee-8c9b-4ab8-bb73-5aee28110ffa"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Safety and effectiveness of EMERPHED and EMERPHED-PFS in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240916"/>
                     <component>
                        <section ID="s24">
                           <id root="58df7364-a7e8-4ce5-b288-53aae71ba040"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Animal Toxicity Data</content>
                              </paragraph>
                              <paragraph>In a study in which juvenile rats were administered intravenous bolus doses of 2, 10, or 60 mg/kg ephedrine sulfate daily from Postnatal Day 35 to 56, an increased incidence of mortality was noted at the high dose of 60 mg/kg. The no-adverse-effect level was 10 mg/kg (approximately 1.9 times a maximum daily dose of 50 mg in a 60 kg person based on body surface area)</paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="0509947e-f93f-4983-b4a8-7972743644b2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Clinical studies of ephedrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="64eb7982-15e0-45f5-8915-475cbdc1e3c6"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment
</title>
                     <text>
                        <paragraph>Ephedrine and its metabolite are excreted in urine. In patients with renal impairment, excretion of ephedrine is likely to be affected with a corresponding increase in elimination half-life, which will lead to slow elimination of ephedrine and consequently prolonged pharmacological effect and potentially adverse reactions. Monitor patients with renal impairment carefully after the initial bolus dose for adverse events.
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="68e3e689-ec08-4464-9d0a-26af8c98de60"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10. OVERDOSAGE
</title>
               <text>
                  <paragraph>Overdose of EMERPHED and EMERPHED-PFS can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.</paragraph>
               </text>
               <effectiveTime value="20240916"/>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="7fc1e64b-52c2-4148-a0c9-975825dfbb3e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11. DESCRIPTION
</title>
               <text>
                  <paragraph>EMERPHED / EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless, sterile solution for intravenous injection. The chemical name of ephedrine sulfate is benzenemethanol, α-[1-(methylamino)ethyl]-, [<content styleCode="italics">R-</content>(<content styleCode="italics">R*,S*</content>)]-, sulfate (2:1) (salt), and the molecular weight is 428.5 g/mol. Its structural formula is depicted below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L0048257c-28e8-45f8-bd2e-c3531885775d"/>
                  </paragraph>
                  <paragraph>
                     <content>Ephedrine sulfate is freely soluble in water and ethanol, very slightly soluble in chloroform, and practically insoluble in ether. Each mL contains ephedrine sulfate, USP 5 mg (equivalent to 3.8 mg ephedrine base), 0.9% sodium chloride, USP in water for injection. The pH range is 4.5 to 7.0.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="L0048257c-28e8-45f8-bd2e-c3531885775d">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epf structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s29">
               <id root="e01d6032-8dad-489d-aeab-f3e7c3c67233"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12. CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20210831"/>
               <component>
                  <section ID="s30">
                     <id root="5acacfcf-864d-4eaa-97c6-961da9091cf0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Ephedrine sulfate is a sympathomimetic amine that directly acts as an agonist at α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic stimulation is caused by norepinephrine release from sympathetic nerves.
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="7a5ce2ca-dfe8-47fb-a48b-ac323293acf8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>Ephedrine stimulates heart rate and cardiac output and variably increases peripheral resistance; as a result, ephedrine usually increases blood pressure. Stimulation of the α-adrenergic receptors of smooth muscle cells in the bladder base may increase the resistance to the outflow of urine. Activation of β- adrenergic receptors in the lungs promotes bronchodilation.
</paragraph>
                        <paragraph>The overall cardiovascular effect from ephedrine is the result of a balance among α-1 adrenoceptor- mediated vasoconstriction, β-2 adrenoceptor- mediated vasoconstriction, and β-2 adrenoceptor-mediated vasodilatation. Stimulation of the β-1 adrenoceptors results in positive inotrope and chronotrope action.
</paragraph>
                        <paragraph>Tachyphylaxis to the pressor effects of ephedrine may occur with repeated administration [<content styleCode="italics">see Warnings and Precautions <linkHtml href="#s10">5.2</linkHtml>
                           </content>].
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="9ff6fb95-92c9-4a4f-996d-71b0771eb588"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>Publications studying pharmacokinetics of oral administration of (-)-ephedrine support that (-)-ephedrine is metabolized into norephedrine. However, the metabolism pathway is unknown. Both the parent drug and the metabolite are excreted in urine. Limited data after IV administration of ephedrine support similar observations of urinary excretion of drug and metabolite. The plasma elimination half-life of ephedrine following oral administration was about 6 hours.
</paragraph>
                        <paragraph>Ephedrine crosses the placental barrier <content styleCode="italics">[see Use in Specific Populations <linkHtml href="#s15">8.1</linkHtml>]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20210831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s33">
               <id root="99b9d049-b803-43a9-ba94-2e22ff18ab8d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13. NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20210831"/>
               <component>
                  <section ID="s34">
                     <id root="4c589bc7-5133-47de-a93a-ea7160a14dfb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <effectiveTime value="20210831"/>
                     <component>
                        <section ID="s35">
                           <id root="66023486-8157-4a98-ab79-511e8c8a55af"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>: Two-year feeding studies in rats and mice conducted under the National Toxicology Program (NTP) demonstrated no evidence of carcinogenic potential with ephedrine sulfate at doses up to 10 mg/kg/day and 27 mg/kg/day (approximately 2 times and 3 times the maximum human recommended dose on a mg/m2 basis, respectively).
</paragraph>
                           </text>
                           <effectiveTime value="20210831"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s36">
                           <id root="f69f135b-33f9-43e4-9bf3-d13098443c82"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>: Ephedrine sulfate tested negative in the in vitro bacterial reverse mutation assay, the in vitro mouse lymphoma assay, the in vitro sister chromatid exchange, the in vitro chromosomal aberration assay, and the in vivo rat bone marrow micronucleus assay.
</paragraph>
                           </text>
                           <effectiveTime value="20210831"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s37">
                           <id root="b83a0285-5355-4852-ad4a-a79ef0cf2e08"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>: There was no impact on fertility or early embryonic development in a study in which male rats were administered intravenous bolus doses of 0, 2, 10, or 60 mg/kg ephedrine sulfate (up to 12 times the maximum recommended human dose of 50 mg based on body surface area) for 28 days prior to mating and through gestation and females were treated for 14 days prior to mating through Gestation Day 7.
</paragraph>
                           </text>
                           <effectiveTime value="20210831"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s38">
               <id root="4d9a5361-2f34-4e28-8bf4-6f14a41d1ae6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14. CLINICAL STUDIES
</title>
               <text>
                  <paragraph>The evidence for the efficacy of EMERPHED / EMERPHED-PFS (ephedrine sulfate injection) is derived from the published literature. Increases in blood pressure following administration of ephedrine were observed in 14 studies, including 9 where ephedrine was used in pregnant women undergoing neuraxial anesthesia during Cesarean delivery, 1 study in non-obstetric surgery under neuraxial anesthesia, and 4 studies in patients undergoing surgery under general anesthesia. Ephedrine has been shown to raise systolic and mean blood pressure when administered as a bolus dose following the development of hypotension during anesthesia.</paragraph>
               </text>
               <effectiveTime value="20240916"/>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="135c5a2c-c548-4744-be4b-c672f310204a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16. HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>EMERPHED (ephedrine sulfate injection) is a clear, colorless solution available as single-dose vials containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows:</paragraph>
                  <table width="100%" border="1">
                     <caption/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold"> NDC</content>
                           </td>
                           <td>
                              <content styleCode="bold"> Presentation</content>
                           </td>
                        </tr>
                        <tr>
                           <td> 14789-250-07</td>
                           <td> 10 mL clear glass, single-dose vial; strength 50 mg/10 mL (5 mg/mL)</td>
                        </tr>
                        <tr>
                           <td> 14789-250-10</td>
                           <td> 10 mL vials packaged in a carton of 10</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless solution available as single-dose pre-filled syringes containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows:</paragraph>
                  <table width="100%" border="1">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold"> NDC</content>
                           </td>
                           <td>
                              <content styleCode="bold">Presentation </content>
                           </td>
                        </tr>
                        <tr>
                           <td> 14789-251-09</td>
                           <td> 5 mL clear glass, single-dose pre-filled syringe; strength 25 mg/5 mL (5 mg/mL)</td>
                        </tr>
                        <tr>
                           <td> 14789-251-10</td>
                           <td> 5 mL pre-filled syringes packaged in a carton of 10</td>
                        </tr>
                        <tr>
                           <td> 14789-252-09</td>
                           <td> 10 mL clear glass, single-dose pre-filled syringe; strength 50 mg/10 mL (5 mg/mL)</td>
                        </tr>
                        <tr>
                           <td> 14789-252-10        </td>
                           <td> 10 mL pre-filled syringes packaged in a carton of 10</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph>The single-dose prefilled syringes, each fitted with a removable tip cap and plunger rods, are presented in a carton.</paragraph>
                  <paragraph>EMERPHED (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and EMERPHED-PFS (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and 25 mg/5 mL (5 mg/mL) are not made with natural rubber latex.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Store in carton until time of use. For single dose only. Discard unused portion.</paragraph>
                  <paragraph>The single-dose prefilled syringe is intended for use in one patient during one surgical procedure.</paragraph>
                  <paragraph/>
                  <paragraph>Patent, www.emerphed.com/patent</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured in Italy for:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L8dfd86c7-bbef-4006-af20-3c2a381974c2"/>
                  </paragraph>
                  <paragraph>Nexus Pharmaceuticals, LLC</paragraph>
                  <paragraph>400 Knightsbridge Parkway</paragraph>
                  <paragraph>Lincolnshire, IL 60069</paragraph>
                  <paragraph>USA</paragraph>
                  <paragraph>EPFPI01ITR06</paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="L8dfd86c7-bbef-4006-af20-3c2a381974c2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="nexus bw.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s40">
               <id root="616cb000-f1a1-4d7a-a7e1-6cf8ecb0d8a2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 5 mg/mL Carton Label</content>
                  </paragraph>
                  <paragraph>NDC 14789-<content styleCode="bold">252</content>-10</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">EMERPHED</content>
                     <sup>®</sup>
                     <content styleCode="bold">-PFS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(ephedrine sulfate injection)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg/10 mL</content> (5 mg/mL)<br/>(equivalent to 38 mg/10 mL ephedrine base)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Premixed formulation -Do not dilute</content>
                  </paragraph>
                  <paragraph>For Intravenous Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">10 x 10 mL Single-dose Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>NEXUS<br/>PHARMACEUTICALS</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L42c0ee17-3074-45fe-b4e5-25be385390f7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="L42c0ee17-3074-45fe-b4e5-25be385390f7">
                     <text>Principal Display Panel – 5 mg/mL Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epfct04itr04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="5383220f-e611-4518-bfa8-51eeff99d2f7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 5 mg/mL Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 14789-252-09</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">EMERPHED</content>
                     <sup>®</sup>
                     <content styleCode="bold">-EPF</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(ephedrine sulfate injection)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg/10 mL</content> (5 mg/mL)<br/>(equivalent to 38 mg/5 mL ephedrine base)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Premixed formulation –Do not dilute</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mL Single-dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld1cf3363-5ab8-4022-850d-4e6a4277fcd7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="Ld1cf3363-5ab8-4022-850d-4e6a4277fcd7">
                     <text>Principal Display Panel – 5 mg/mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epfls02itr04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="0984fc4c-6ccd-40d3-9101-4239610cd551"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 25 mg/5 mL Carton Label</content>
                  </paragraph>
                  <paragraph>NDC 14789-<content styleCode="bold">251</content>-10</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">EMERPHED</content>
                     <sup>®</sup>
                     <content styleCode="bold">-EPF</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(ephedrine sulfate injection)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">25 mg/5 mL</content> (5 mg/mL)<br/>(equivalent to 19 mg/5 mL ephedrine base)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Premixed formulation -Do not dilute</content>
                  </paragraph>
                  <paragraph>For Intravenous Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">10 x 5 mL Single-dose Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>NEXUS<br/>PHARMACEUTICALS</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Le9262ee6-fc61-48d2-82a5-328eefc0ac6c"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="Le9262ee6-fc61-48d2-82a5-328eefc0ac6c">
                     <text>Principal Display Panel – 25 mg/5 mL Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epfct02itr04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s43">
               <id root="056314cd-6ded-488f-ad8d-7b7bb6197a83"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 25 mg/5 mL Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 14789-251-09</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">EMERPHED</content>
                     <sup>®</sup>
                     <content styleCode="bold">-EPF</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(ephedrine sulfate injection)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">25 mg/5 mL</content> (5 mg/mL)<br/>(equivalent to 19 mg/5 mL ephedrine base)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Premixed formulation –Do not dilute</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L0127012a-6d32-4281-8e8e-cc67ecb95ebc"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240918"/>
               <component>
                  <observationMedia ID="L0127012a-6d32-4281-8e8e-cc67ecb95ebc">
                     <text>Principal Display Panel – 25 mg/5 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="epfls01itr04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>